BCTX — Briacell Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Briacell’S Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® And Control Group In Metastatic Breast Cancer
Brief: Briacell Phase 2 Survival Achievement 52% Of Patients Surpass One-Year Milestone In Metastatic Breast Cancer
Brief: BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network And Smilow Cancer Hospital At Yale New Haven
BriaCell gains on safety review of breast cancer therapy study
Brief: Briacell Announces Positive Recommendation From Data Safety Monitoring Board For Pivotal Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Therapeutics Corp - Bria-Imt Receives FDA Fast Track Designation For Phase 3 Study
Brief: Briacell Therapeutics Announces Closing Of $13.8 Million Public Offering
Brief: Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million
Brief: BriaCell Confirms 100% Resolution Of Lung Metastasis With Bria-OTS™
Brief: Briacell Therapeutics Files For Offering Of Up To 2.3 Mln Common Units, Up To 2.3 Mln Pre-Funded Units
Brief: BriaCell Enrollment Pace Accelerating In Phase 3 Clinical Study In Advanced Metastatic Breast Cancer (Bria-ABC)
Brief: Briacell Phase 2 Survival Data Beats Leading Standard In Hr+ Breast Cancer
Brief: Briacell Therapeutics Corp - Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Briacell Therapeutics Announces Closing Of Public Offering
Brief: Briacell Therapeutics Prices Public Offering Of 762,500 Shares At $4 Each
Brief: Briacell Therapeutics Announces Proposed Public Offering Of Common Shares
Brief: Briacell Therapeutics Announces Closing Of $5.5 Million Public Offering
Brief: Briacell Therapeutics Prices Public Offering Of 7.4 Mln Shares And Warrants At $0.75 Each
Brief: BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer